Virtual Library
Start Your Search
Wenyu Sun
Author of
-
+
P1.07 - Immunology and Immunotherapy (ID 693)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.07-006 - Altered Expression of Programmed Death-1 Receptor (PD-1) and Its Ligand PD-L1, PD-L2 after Neo-Adjuvant Chemotherapy in Lung Cancer (ID 7930)
09:30 - 16:00 | Presenting Author(s): Wenyu Sun
- Abstract
Background:
Immunotherapy is a new research direction in the treatment of lung cancer. PD1/PD-L1, PD-L2 pathway as representative of the immune checkpoint, play critical roles in the development and progression of cancer. And the expression of PD-1, PD-L1, PD-L2 were associated with therapeutic effect. Many studys have shown that many factors may effect the expression of PD1, PD-L1, PD-L2, such as chemotherapy. The present study aims to examine the impact of neo-adjuvant chemotherapy (NAC) on PD-1, PD-L1, PD-L2 expression in lung cancer.
Method:
In this study, tumor samples were obtained from 26 patients who confirmed primary lung cancer prior to and after NAC（platinum-based）from June, 2009 to May, 2016 in the First Hospital of Jilin University. Expression of PD-1, PD-L1, PD-L2 in lung cancer tumor specimens were assessed by immunohistochemistry (IHC). Using 5%, 10%, 20%, 30%, 50% expression threshold to define PD-1, PD-L1, PD-L2 positive status, respectively. The variation of PD-1, PD-L1, PD-L2 in prior to and after NAC were evaluated by Matching chi-square test. Besides that, Spearman's rank correlation and non-parametric test were used to calculate the relationship between the changes of PD-1, PD-L1, PD-L2 and tumor shrinkage rate, interval from the end of NAC to operation, pathological type, gender, smoking or not. P value ＜ 0.05 was considered statistically significant.
Result:
Using 5%, 10%, 20% expression threshold to define PD-L1 positive status, 65.4%(17/26), 53.8%(14/26), 42.3%(11/26) were found to be PD-L1 positive prior to NAC, and 92.3% (24/26), 80.8%(21/26), 69.2%(18/26) expressed positively after NAC, PD-L1 was up-regulated after NAC（p=0.003, p=0.016, p=0.016）, however, there were no obviously statistical significance about the expression of PD-L1（p＞0.05）when using 30%, 50% expression threshold. The expression of PD1, PD-L2 were not show any statistical significance before and after NAC（p＞0.05）. Furthermore, there were no relationship between the changes of PD-1, PD-L1, PD-L2 and pathological type, interval from the end of NAC to operation, gender, smoking or not (p＞0.05）.Figure 1
Conclusion:
The expression of PD-L1 was up-regulated after NAC when using 5%, 10%, 20% expression threshold, there were obviously statistical significance. No correlations existed between the variation of PD-1, PD-L1, PD-L2 and tumor shrinkage rate, interval from the end of NAC to operation, pathological type, gender, smoking or not.
